DNTH icon

Dianthus Therapeutics

22.15 USD
+0.38
1.75%
At close Jan 31, 4:00 PM EST
1 day
1.75%
5 days
4.93%
1 month
1.61%
3 months
-20.50%
6 months
-25.62%
Year to date
-4.53%
1 year
16.58%
5 years
101.36%
10 years
101.36%
 

About: Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Employees: 53

0
Funds holding %
of 6,831 funds
0
Analysts bullish %
of 3 analysts

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

317% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 6

55% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 20

23% more funds holding

Funds holding: 74 [Q2] → 91 (+17) [Q3]

12% more capital invested

Capital invested by funds: $770M [Q2] → $859M (+$89.3M) [Q3]

5.57% more ownership

Funds ownership: 101.33% [Q2] → 106.9% (+5.57%) [Q3]

0% more call options, than puts

Call options by funds: $11K | Put options by funds: $11K

29% less funds holding in top 10

Funds holding in top 10: 7 [Q2] → 5 (-2) [Q3]

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$40
81%
upside
Avg. target
$49
123%
upside
High target
$56
153%
upside

3 analyst ratings

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Swayampakula Ramakanth
31% 1-year accuracy
58 / 189 met price target
81%upside
$40
Buy
Reiterated
11 Nov 2024
Oppenheimer
Leland Gershell
44% 1-year accuracy
24 / 55 met price target
135%upside
$52
Outperform
Maintained
11 Nov 2024
Raymond James
Steven Seedhouse
13% 1-year accuracy
2 / 15 met price target
153%upside
$56
Outperform
Maintained
8 Nov 2024

Financial journalist opinion

Neutral
GlobeNewsWire
2 days ago
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences
NEW YORK and WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during the month of February:
Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences
Neutral
GlobeNewsWire
3 weeks ago
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
NEW YORK and WALTHAM, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation at the 43rd Annual J.P. Morgan Healthcare Conference. Marino Garcia, Chief Executive Officer, will present a corporate overview on Wednesday, January 15, 2025 at 9:00 a.m. PST / 12:00 p.m. EST in San Francisco.
Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference
Negative
Zacks Investment Research
2 months ago
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $3.78 per share a year ago.
Dianthus Therapeutics, Inc. (DNTH) Reports Q3 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
2 months ago
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Initiation of a single, two-part, pivotal Phase 3 trial of DNTH103 in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) anticipated by YE'24
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results
Neutral
GlobeNewsWire
2 months ago
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced the company's participation and corporate overview presentations by Marino Garcia, Chief Executive Officer, at the following healthcare investor conferences during November and December 2024:
Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences
Neutral
GlobeNewsWire
3 months ago
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
NEW YORK and WALTHAM, Mass., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today announced two poster presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting, taking place October 15-18, 2024 in Savannah, Georgia.
Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting
Positive
Zacks Investment Research
3 months ago
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?
Dianthus Therapeutics, Inc. (DNTH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Strength Seen in Dianthus Therapeutics, Inc. (DNTH): Can Its 5.7% Jump Turn into More Strength?
Negative
Zacks Investment Research
5 months ago
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
Dianthus Therapeutics, Inc. (DNTH) came out with a quarterly loss of $0.51 per share versus the Zacks Consensus Estimate of a loss of $0.50. This compares to loss of $0.80 per share a year ago.
Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates
Neutral
GlobeNewsWire
5 months ago
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
Phase 2 MaGic trial in generalized Myasthenia Gravis (gMG) ongoing;  top-line results anticipated in 2H'25 IND for Phase 2 MoMeNtum trial in Multifocal Motor Neuropathy (MMN) cleared by FDA in June;  top-line results anticipated in 2H'26 Phase 2 trial in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) to initiate 2H'24  Approximately $361 million of cash provides runway into 2H'27 NEW YORK and WALTHAM, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the second quarter ending June 30, 2024, and provided an update on recent business achievements.
Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results
Positive
Seeking Alpha
6 months ago
Dianthus: Improved Autoimmune Disorder Targeting With Classical Pathway Inhibition
Dianthus Therapeutics, Inc.'s DNTH103 is being evaluated in the phase 2 MaGic trial, which is targeting patients with generalized myasthenia gravis. The global myasthenia gravis treatment market size is estimated to reach $2.2 billion by 2028; Up to 85% of MG patients are said to have the generalized form of the disease. Two other indications being explored in the pipeline with the advancement of DNTH103 are multifocal motor neuropathy and chronic inflammatory demyelinating polyneuropathy.
Dianthus: Improved Autoimmune Disorder Targeting With Classical Pathway Inhibition
Charts implemented using Lightweight Charts™